Finding new ways to remove disease-causing proteins
Chemical Proteomics Approach to Discover Novel Small Molecule E3 Ligase recruiters for Targeted Protein degradation (TPD)
['FUNDING_OTHER'] · EMORY UNIVERSITY · NIH-11144970
This project looks for new chemical tools that can help the body get rid of harmful proteins linked to various diseases.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11144970 on ClinicalTrials.gov |
What this research studies
Many diseases are caused by proteins that don't work right or are present in too high amounts. Current medicines often block these proteins, but sometimes that's not enough. This research explores a new method called Targeted Protein Degradation (TPD), which uses special small molecules to tag unwanted proteins for removal by the body's natural cleanup system. We are working to discover new ways to guide this cleanup system to a wider range of disease-causing proteins, especially those that are currently hard to treat.
Who could benefit from this research
Good fit: This foundational research is not directly recruiting patients but aims to develop new therapeutic strategies that could eventually benefit individuals with a wide range of diseases caused by problematic proteins.
Not a fit: Patients seeking immediate treatment options will not directly benefit from this early-stage research, as it focuses on drug discovery methods rather than clinical application.
Why it matters
Potential benefit: If successful, this work could lead to entirely new types of medicines that can effectively remove disease-causing proteins, offering hope for conditions currently without good treatment options.
How similar studies have performed: Other research groups have successfully used similar chemical approaches to target specific proteins for degradation, and this project aims to expand on those successes by exploring new chemical strategies.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHANG, JAEWON — EMORY UNIVERSITY
- Study coordinator: CHANG, JAEWON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.